We are live on ! Find out more
EA

Emerald Advisers Portfolio holdings

AUM $4.25B
1-Year Est. Return 141.71%
This Fund
S&P 500
This Quarter Est. Return
+42.53%
1 Year Est. Return
+141.71%
3 Year Est. Return
+486.97%
5 Year Est. Return
+675.33%
10 Year Est. Return
+5,134.3%
AUM
$2.29B
AUM Growth
+$566M
Cap. Flow
-$11.7M
Cap. Flow %
-0.51%
Top 10 Hldgs %
20.65%
Holding
346
New
133
Increased
78
Reduced
97
Closed
28

Top Sells

Rank Stock Value
1
CIEN icon
Ciena
CIEN
+$37.3M
2
TREX icon
Trex
TREX
+$22.9M
3
CHGG icon
Chegg
CHGG
+$20.7M
4
TDOC icon
Teladoc Health
TDOC
+$19.2M
5
HAE icon
Haemonetics
HAE
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 25.95%
2 Technology 15.55%
3 Industrials 15.21%
4 Consumer Discretionary 13.91%
5 Consumer Staples 10.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TREE icon
76
LendingTree
TREE
$393M
$11.4M 0.5%
39,262
-31,145
-44% -$7.52M
NEWR
77
DELISTED
New Relic, Inc.
NEWR
$11.4M 0.49%
164,746
-6,730
-4% -$402K
PLCE icon
78
Children's Place
PLCE
$62.7M
$11.2M 0.49%
298,897
+132,710
+80% +$4.51M
EVRI
79
DELISTED
Everi Holdings
EVRI
$11M 0.48%
2,137,089
+302,830
+17% +$1.54M
PRFT
80
DELISTED
Perficient Inc
PRFT
$10.8M 0.47%
303,139
-149,851
-33% -$4.97M
LIVN icon
81
LivaNova
LIVN
$4.47B
$10.6M 0.46%
220,843
+2,660
+1% +$133K
IPHI
82
DELISTED
INPHI CORPORATION
IPHI
$10.4M 0.45%
88,420
+32,690
+59% +$3.44M
ASMB icon
83
Assembly Biosciences
ASMB
$736M
$10.3M 0.45%
36,837
+402
+1% +$93.8K
ACA icon
84
Arcosa
ACA
$7.14B
$10.1M 0.44%
240,050
+550
+0.2% +$21.2K
COLL icon
85
Collegium Pharmaceutical
COLL
$772M
$10.1M 0.44%
578,313
-187,517
-24% -$3.67M
NFE icon
86
New Fortress Energy
NFE
$79.7M
$9.95M 0.43%
767,386
+9,134
+1% +$115K
RETA
87
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$9.9M 0.43%
63,472
-51,064
-45% -$7.76M
VG
88
DELISTED
Vonage Holdings Corporation
VG
$9.76M 0.43%
+970,158
New +$8.7M
PASG icon
89
Passage Bio
PASG
$15.3M
$9.64M 0.42%
17,637
-93
-0.5% -$41.8K
SMTC icon
90
Semtech
SMTC
$12.6B
$9.54M 0.42%
+182,700
New +$8.55M
STAG icon
91
STAG Industrial
STAG
$7.27B
$9.26M 0.4%
315,703
+2,250
+0.7% +$59.2K
BDSI
92
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$9.18M 0.4%
2,106,473
+5,844
+0.3% +$26.3K
AIMT
93
DELISTED
Aimmune Therapeutics
AIMT
$8.78M 0.38%
525,423
-1,727
-0.3% -$29.3K
ADC icon
94
Agree Realty
ADC
$9.05B
$8.67M 0.38%
131,969
-450
-0.3% -$28.7K
MMSI icon
95
Merit Medical Systems
MMSI
$5.29B
$8.55M 0.37%
187,355
-112,562
-38% -$4.54M
ECVT icon
96
Ecovyst
ECVT
$1.12B
$8.38M 0.37%
633,180
-82,871
-12% -$974K
OYST
97
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$8.22M 0.36%
284,485
+57,604
+25% +$1.74M
HAE icon
98
Haemonetics
HAE
$4.68B
$7.87M 0.34%
87,835
-186,315
-68% -$18.8M
CTLP
99
DELISTED
Cantaloupe
CTLP
$7.79M 0.34%
1,111,521
-3,550
-0.3% -$24.9K
AVNT icon
100
Avient
AVNT
$3.94B
$7.7M 0.34%
+293,500
New +$6.81M

Similar funds

Emerald Advisers's Q2 2020 Portfolio in Review

As of Q2 2020, Emerald Advisers held 346 positions worth $2.29B, up 33% from $1.73B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Emerald Advisers's Q2 2020 filing shows 133 new, 78 increased, 97 reduced and 28 closed positions. Its largest new stake was Installed Building Products: 260,330 shares worth $17.9M. The largest sale was Ciena, an estimated $37.3M.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 30% a quarter earlier, followed by Technology and Industrials.

  • Emerald Advisers's largest Q2 2020 buy was Installed Building Products: 260,330 shares worth $17.9M.
  • Emerald Advisers added most to National Vision in Q2 2020, an estimated $14.6M increase.
  • Emerald Advisers's biggest Q2 2020 reduction was Ciena, cutting an estimated $37.3M.
  • Emerald Advisers fully exited Teladoc Health in Q2 2020, selling an estimated $19.2M.
  • Emerald Advisers's ten largest holdings make up 21% of its $2.29B portfolio in Q2 2020.
  • Emerald Advisers opened 133 new positions and closed 28 in Q2 2020.
  • Emerald Advisers's portfolio value rose 33% quarter-over-quarter to $2.29B.

Based on Emerald Advisers's 13F filing for Q2 2020, filed 28 Jul 2020.